Business model: independent film co-financier/co-producer focusing on structured senior/priority recoupment positions and building owned/controlled IP; pivoted away from third‑party consulting in 2025. 2025 revenue rose to $853,017 (from $52,677 in 2024), largely from BARRON’S COVE-related receivables and fees; net loss narrowed to $534,440 (from $2,270,258). Accumulated deficit ~ $7.8 million at 12/31/2025; negative working capital of ~$435,000; cash and cash equivalents of $124 at year‑end. Accounts receivable of $1,150,000 at 12/31/2025 reflects APHP’s priority collection rights on BARRON’S COVE per the 12/29/2025 SSS amendment. Operating expenses fell: G&A $1,403,010 (from $2,252,130), driven by lower stock‑based compensation ($379k vs. $1.26m in 2024). Interest income $97,027 (mainly from Barron’s Cove loan); interest expense $70,898. Film slate and participation: BARRON’S COVE (released 6/6/2025), POSE (12/5/2025), THIEVES HIGHWAY (12/16/2025), PROTECTOR (U.S. theatrical 3/6/2026), MOTION (post‑production; targeted 2Q 2026). Key amendments/agreements with SSS Entertainment: 8/1/2025 agreement and 12/29/2025 amendment establishing APHP’s $1,150,000 first‑priority Net Revenues on BARRON’S COVE, then 85%/15% split to SSS/APHP until SSS recoupment, then 100% to APHP. Multi‑Film Investment & Compensation Agreement effective 1/27/2026 (board‑ratified 3/12/2026) covering POSE (fixed $575k payable due by 1/31/2027 after $175k partial), MOTION ($500k funding assigned economics), and an untitled SSS picture ($200k contemplated). Financing: Equity Line of Credit with RH2 Equity Partners up to the lesser of $100 million or the share cap (8/28/2025); Labrys Fund II promissory notes (9/22/2025: $115k; 1/20/2026: $172.5k incl. OID, convertible on default/missed amortization). Capital structure: 1,001,000,000 authorized (1,000,000,000 common; 1,000,000 preferred); 113,599,325 common shares outstanding as of 3/25/2026; CEO controls ~97.66% voting power via 3,839 Series A preferred. Going concern risk disclosed; company expects to continue incurring expenses and seeks capital through debt/equity financings, including equity‑linked instruments.